Nanobiotix (NBTX) Cash & Current Investments (2018 - 2025)
Nanobiotix's (NBTX) quarterly Cash & Current Investments came in at $61.4 million in Q4 2025, up 15.53% year-on-year from $53.1 million in Q4 2024, and up 88.23% quarter-over-quarter from $32.6 million in Q2 2025.
Nanobiotix (NBTX) Cash & Current Investments (2018 - 2025) Analysis & Trends
Nanobiotix's Cash & Current Investments history runs 8 years deep, the most recent figure standing at $61.4 million for Q4 2025.
- On a quarterly basis, Cash & Current Investments rose 15.53% year-over-year to $61.4 million in Q4 2025; TTM through Dec 2025 was $61.4 million, a 15.53% increase from a year earlier, with the FY2025 full-year figure at $59.6 million, up 12.13% from the prior year.
- Cash & Current Investments rose to $61.4 million in Q4 2025 per NBTX's latest filing, from $32.6 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $123.2 million in Q2 2021 and bottomed at $23.6 million in Q2 2023.
- The 5-year median for Cash & Current Investments is $64.3 million (2022), against an average of $65.2 million.
- Across the five-year window, Cash & Current Investments plunged 64.98% in 2023 and soared 203.3% in 2024, its largest moves.
- Year by year, Cash & Current Investments stood at $96.0 million in 2021, then tumbled by 56.02% to $42.2 million in 2022, then surged by 91.82% to $81.0 million in 2023, then slumped by 34.38% to $53.1 million in 2024, then grew by 15.53% to $61.4 million in 2025.
- Per Business Quant, the three latest NBTX Cash & Current Investments figures stand at $61.4 million (Q4 2025), $32.6 million (Q2 2025), and $53.1 million (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 3.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 61.40 Mn |
| Jun 30, 2025 | 32.62 Mn |
| Dec 31, 2024 | 53.15 Mn |
| Jun 30, 2024 | 71.44 Mn |
| Dec 31, 2023 | 81.00 Mn |
| Jun 30, 2023 | 23.55 Mn |
| Dec 31, 2022 | 42.23 Mn |
| Jun 30, 2022 | 67.25 Mn |
| Dec 31, 2021 | 96.00 Mn |
| Jun 30, 2021 | 123.24 Mn |
| Dec 31, 2020 | 142.06 Mn |
| Dec 31, 2019 | 38.85 Mn |
| Dec 31, 2018 | 41.32 Mn |